Table 3.
Underlying conditions and clinical findings in patients with COVID-19 pneumonia in the B.1.1.7 group.
| Variables | Community-acquired pneumonia | Nursing and healthcare-associated pneumonia | p value |
|---|---|---|---|
| No. of patients | 260 | 75 | |
| Median age (IQR), years | 62 (46–72) | 72 (64–82) | <0.0001 |
| No. of males/females | 182/78 | 45/30 | 0.1228 |
| No. (%) of patients with comorbid illnesses | |||
| Diabetes mellitus | 47 (18.1) | 18 (24.0) | 0.2506 |
| Chronic lung disease | 34 (13.1) | 9 (12.0) | >0.9999 |
| Chronic heart disease | 16 (6.2) | 7 (9.3) | 0.3124 |
| Cerebrovascular disease | 8 (3.1) | 12 (16.0) | 0.0002 |
| Chronic renal disease | 8 (3.1) | 16 (21.3) | <0.0001 |
| Neoplastic disease | 6 (2.3) | 8 (10.7) | 0.0042 |
| Chronic liver disease | 6 (2.3) | 3 (4.0) | 0.4246 |
| Autoimmune disease | 5 (1.9) | 2 (2.7) | 0.6558 |
| No. (%) of patients with the following clinical signs and symptoms | |||
| History of fever (≥37.0 °C) | 225 (86.5) | 70 (90.3) | 0.1554 |
| Cough | 169 (65.0) | 40 (53.3) | 0.0786 |
| Fatigue | 94 (36.2) | 16 (21.3) | 0.0176 |
| Shortness of breath | 91 (35.0) | 18 (24.0) | 0.0928 |
| Sore throat | 57 (21.9) | 11 (14.7) | 0.1944 |
| Loss of taste | 52 (20.0) | 3 (4.0) | 0.0006 |
| Anosmia | 47 (18.1) | 2 (2.7) | 0.0003 |
| Headache | 32 (12.3) | 1 (1.3) | 0.0033 |
| Diarrhea | 27 (10.4) | 0 | 0.0012 |
| Sputum production | 35 (13.5) | 19 (25.3) | 0.0197 |
| Runny nose | 23 (8.8) | 1 (1.3) | 0.0223 |
| Joint pain | 11 (4.2) | 3 (4.0) | >0.9999 |
| Chest pain | 5 (1.9) | 0 | 0.5911 |
| Muscle ache | 4 (1.5) | 0 | 0.5787 |
| Nausea or vomiting | 11 (4.2) | 3 (4.0) | >0.9999 |
| Abdominal pain | 1 (0.4) | 0 | >0.9999 |
| No. (%) of patients with each pneumonia severity score | |||
| 0 | 56 (21.5) | 1 (1.3) | <0.0001 |
| 1 | 104 (40.0) | 30 (40.0) | >0.9999 |
| 2 | 63 (24.2) | 25 (33.3) | 0.1362 |
| 3 | 37 (14.2) | 19 (25.3) | 0.0338 |
| 4 | 0 | 0 | >0.9999 |
| 5 | 0 | 0 | >0.9999 |
| No. (%) of patients with treatment | |||
| Antibiotic therapy | 67 (25.8) | 46 (61.3) | <0.0001 |
| Antiviral therapy | 191 (73.5) | 74 (98.7) | <0.0001 |
| Glucocorticoid therapy | 172 (66.2) | 64 (85.3) | 0.001 |
| No. (%) of patients with respiratory care | |||
| HFNC | 73 (28.1) | 18 (24.0) | 0.557 |
| IMV | 96 (36.9) | 39 (52.0) | 0.023 |
| ECMO | 23 (8.8) | 7 (9.3) | 0.823 |
| No. (%) of patients admitted to intensive care unit | 119 (45.8) | 46 (61.3) | 0.0187 |
| No. (%) of patients with in-hospital mortality | 9 (3.5) | 16 (21.3) | <0.0001 |
Continuous values are presented as medians and interquartile ranges (IQRs) and categorical/binary values as counts and percentages. HFNC, high flow nasal canula. IMV, invasive mechanical ventilation. ECMO, extracorporeal membrane oxygen.